In conclusion, while GLP-1RAs and GLP-1/GIP dual agonists offer significant clinical advantages, ongoing research and vigilant monitoring of their adverse effects and safety are essential for optimizing their therapeutic application.229,230 Conclusion In summary, GLP-1RAs and dual-receptor agonists targeting both GLP-1 and GIP receptors have introduced significant advancements in the management of endocrine and metabolic disorders and their associated complications, establishing themselves as central therapeutic modalities within this domain
Acknowledgements We acknowledge support from National Institute on Alcohol Abuse and Alcoholism (AA029831), National Institute on Aging (AG057557, AG061388, AG062272, AG07664), from National Cancer Institute Case Comprehensive Cancer Center (CA221718, CA043703, CA2332216)
Rat Models Offer New Insight into GLP-1 Thirst Suppression GLP-1 agonists can also cause thirst suppression, although this side effect is not as widely reported
Add psoriatic arthritis I'd love to see evidence that separates the effect GLP1 has in reducing intake of harmful substances (UPF, smoking, alcohol) which we know drive these long term conditions, versus direct effects of the drug
